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Abstract: The transcription of inducible nitric oxide synthase (iNOS) is activated by a network of proinflammatory sig-
naling pathways. Here we describe the identification of a small molecule that downregulates the expression of iNOS 
mRNA and protein in cytokine-activated cells and suppresses nitric oxide production in vivo. Mechanistic analysis sug-
gests that this small molecule, erstressin, also activates the unfolded protein response (UPR), a signaling pathway trig-
gered by endoplasmic reticulum stress. Erstressin induces rapid phosphorylation of eIF2 and the alternative splicing of 
XBP-1, hallmark initiating events of the UPR. Further, erstressin activates the transcription of multiple genes involved in 
the UPR. These data suggest an inverse relationship between UPR activation and iNOS mRNA and protein expression un-
der proinflammatory conditions. 
INTRODUCTION  
  Nitric oxide (NO) is an important biological second mes-
senger that regulates a wide array of physiologic processes, 
including vasodilation, neurotransmission and immune re-
sponses. NO is generated by three enzymes; the endothelial, 
neuronal, and inducible nitric oxide synthases (NOSs). Ex-
pression of the inducible NOS (iNOS) gene is upregulated in 
various cell types in response to proinflammatory agents. As 
a result, in certain pathophysiological conditions, such as 
arthritis, asthma and inflammatory bowel disease, the NO 
produced by iNOS contributes to local inflammation, tissue 
damage, and pain [1]. Transcriptional and post-
transcriptional regulation of iNOS is governed by a number 
of well characterized signaling pathways [2], however, addi-
tional undiscovered pathways of regulation may exist. 
  The endoplasmic reticulum (ER) is an intracellular or-
ganelle responsible for the proper synthesis and folding of 
secreted and membrane-bound proteins. Many disturbances, 
including aberrant calcium regulation, altered redox status, 
or interference with protein glycosylation, can result in the 
accumulation of unfolded ER client proteins in a phenome-
non referred to as ER stress. To compensate for this in-
creased protein burden, a signaling pathway known as the 
unfolded protein response (UPR) is activated [3]. We have 
identified a novel small molecule activator of the unfolded 
protein response (UPR) pathway in a chemical genetic 
screen for inhibitors of iNOS. The data are consistent with 
the hypothesis that activation of the UPR leads to specific 
downregulation of cytokine-induced iNOS production.  
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MATERIALS AND METHODOLOGY 
Cell Culture 
  A172 human glioblastoma cells, RAW 264.7 mouse 
macrophage cells, HEK293 and HeLa human adenocarci-
noma cells (ATCC) were cultured in DMEM containing 10% 
FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. 
A172 cells were stimulated to express iNOS by adding a 
cocktail containing hIFN- (4,000 U/ml), hTNF- (40 
ng/ml), and hIL-1 (4 ng/ml). RAW 264.7 cells were stimu-
lated with lipopolysacharride (1 g/ml) (Sigma) and mIFN- 
(100 U/ml) (Roche Diagnostics) unless otherwise indicated. 
Nitric Oxide Detection  
  A172 or RAW 264.7 cells were plated in 384- or 1536-
well plates and simultaneously treated with stimulation me-
dia and compound. After 18 hours of incubation NO produc-
tion was measured by adding 2,3-diaminonaphthalene 
(DAN) (10 μg/ml final) (Invitrogen) diluted in DMEM sup-
plemented with hydrochloric acid (0.1N final) and incubated 
for 20 minutes at room temperature. Fluorescence was 
measured after increasing pH with sodium hydroxide (0.12N 
final) [4].  
Cytoblot  
  Protocol was modified from a previously described assay 
[5]. Briefly, RAW 264.7 cells were plated in 384-well format 
and simultaneously treated with stimulation media and com-
pound. After 18 hours incubation, cells were fixed with 
ethanol / acetic acid (95% / 5%) and blocked with PBS/ 4% 
BSA for 1 hour at room temperature. Cells were incubated 
with a 1:250 dilution of iNOS primary antibody (BD Bio-
sciences) in PBS/ 1% BSA for 1.5 hrs at room temperature. 
A 1:2500 dilution of donkey anti-mouse HRP conjugated 
secondary antibody (Jackson ImmunoSciences) in PBS/ 1% 2    Current Chemical Genomics, 2008, Volume 2  Symons et al. 
BSA was added to wells and incubated 1 hour at room tem-
perature. HRP activity was detected with luminol (Santa 
Cruz Biotech) on an Analyst GT plate reader.  
Western Blots 
  RAW 264.7 cells were incubated with stimulation media 
and compound at the indicated times and concentrations.  
  Whole cell extracts were prepared in the presence of pro-
tease inhibitors (Roche) and for eIF-2, phosphatase inhibi-
tors were added (Pierce). Total protein concentration was 
measured using the Advanced Protein Assay (Cytoskeleton, 
Inc) and samples were normalized for loading. Samples were 
run on 4-20% tris-glycine gels or 4-12% Bis-Tris gels (Invi-
trogen) and electro-transferred (Biorad) to nitrocellulose 
membranes (Invitrogen). For iNOS detection, membranes 
were blocked overnight in tris-buffered saline containing 
0.05% (v/v) Tween-20 (TBST) and 3% (w/v) nonfat milk. 
Membranes were then incubated with a 1:2500 dilution of 
murine iNOS (BD Biosciences) primary antibody for 1 hour. 
This was followed by incubation with 1:2000 dilution of 
HRP conjugated goat anti-mouse secondary for 1 hour. For 
eIF2 and eIF2 phosphoSer51, membranes were blocked 
over night in Starting Block (Pierce) containing 0.1% (v/v) 
Tween-20 and incubated in a 1:500 dilution of either anti-
eIF-2 or anti-eIF-2-phospho S51 (Cell Signalling Tech-
nologies) for 2 hours, followed by incubation with 1:2000 
dilution of HRP-conjugated secondary antibody for 1 hour. 
For phospho-STAT1 (Tyr 701) and phospho-STAT3 (Tyr 
705), membranes were blocked overnight in TBST with 5% 
(w/v) nonfat milk. Blots were incubated with 1:1000 dilution 
of the appropriate STAT antibody (Cell Signaling Technol-
ogy) for 2 hours, followed by incubation with goat anti rab-
bit HRP (1:2000) for 1 hour. All membranes were developed 
with WestDura substrate (Pierce) and imaged using a Fluor-
Chem imager (Alpha Innotech Corporation). 
XBP-1 Splicing Assay 
  HeLa cells were seeded in 6-well dishes and treated with 
compound for 1 hour and washed twice with PBS. RNA was 
isolated using the RNeasy kit including on-column DNase 
treatment (Qiagen). cDNA was transcribed using Superscrip-
tIII (Invitrogen) and PCR of a 597bp nucleotide fragment, 
including the 26 nucleotide alternately spliced intron, was 
performed as described previously [6]. 
Quantitative Real Time PCR and Microarray Analysis 
  After incubation with compound and stimulation media, 
A172 or RAW 264.7 cells were lysed in 350 μl buffer RLT, 
homogenized over QiaShredder columns, and total RNA was 
purified using the RNeasy kit with on-column DNase diges-
tion (Qiagen). RNA quality and concentration was deter-
mined using the Bioanalyzer RNA6000 assay (Agilent). 2 g 
of RNA was used in cDNA synthesis reactions (Invitrogen). 
Each cDNA sample was amplified using SYBRgreen-based 
qPCR and a melting curve was determined. For microarray 
studies, 5 g of the RNA was analyzed on U133A 2.0 Gene 
Chips using standard protocols (Affymetrix). Analysis was 
conducted using gcRMA normalization with GeneSpring and 
Spotfire software. 
Cytotoxicity 
  A172 cells were plated in 1536-well plates at 2,500 
cells/well and allowed to adhere for 4 hours. Subsequently 
the cells were simultaneously stimulated with cytokine and 
treated with compound. Cells were then incubated for 6 or 
18 hours followed by addition of ATPlite (Perkin Elmer) to 
determine cellular ATP levels. Luminescence was read on an 
Analyst GT microplate reader. For mitochondrial membrane 
potential measurements, stimulated A172 human glioblas-
toma cells were treated with 10 M ToxoFlavin, 10 M er-
stressin or 10 M nostressin in DMEM with 0.1% DMSO, 
5% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin 
for 6 or 18 hours. Cells were trypsinized and washed twice 
with PBS. Cells were resuspended in 100 l staining buffer 
containing 5 g/ml JC-1 dye (Invitrogen). After incubating 
for 15 minutes at 37ºC, cells were acquired for fluorescent 
measurement using a Becton Dickinson LSRII flow cytome-
ter. After gating on live cells, those which exhibited a fluo-
rescent shift from 590nm to 525nm were considered apop-
totic [7].  
Rat LPS Model 
  Male Lewis rats (Charles River) 150-200 g were admin-
istered a dose of 0.3 mg/kg of lipopolysaccharride - LPS 
(Sigma) dissolved in 0.9% sodium chloride. The intravenous 
injection was given though the penal vein under anesthesia 
with 5% isoflurane in medical grade pure oxygen and main-
tained at 2-3% isoflurane. Drug (30 mg/kg in Encapsin, 5% 
DMSO) or vehicle alone was administered 3 to 5 minutes 
prior to LPS challenge via  intraperitoneal injection. Rats 
were returned to their home cages and sacrificed 6 hours 
later. Blood samples were collected for analysis of nitrates 
(Cayman Chemical Nitrate/Nitrite Flourometric Assay Kit). 
Fluorescence was measured using an Aquest plate reader 
(Molecular Devices). All results are expressed as mean + 
SEM.  
NFB Electrophoretic Mobility Shift Assays 
  DNA binding assays were performed as described previ-
ously. Briefly, 10 μg of nuclear extract was mixed with 1 μl 
of 10 mg/ml BSA, 0.5 μl of 1 mg/ml poly (dI:dC), 50,000 
cpm of 
32P-end-labeled probe, 2 μl of 10X binding buffer 
(100 mM Tris Cl, pH 7.5, 500 mM NaCl, 10 mM DTT, 10 
mM EDTA and 50% glycerol) and 1 μl of antiserum (where 
appropriate) in a 20 μl final reaction volume. Following 15 
minutes of incubation at room temperature, complexes were 
resolved on a 5% native polyacrylamide gel in 0.5 TBE (45 
mM Tris, 45 mM boric acid, 1 mM EDTA). The oligonu-
cleotide probe (top strand) used in this study was NFB, 5’-
 
 
 
 
 
 
Fig. (1). Chemical structure of screening hit and inactive ana-
log. 
Compound 1, a synthetic 3-trifluoromethyl-N-methylpyrazole, 
MW=349.76, inhibits cellular iNOS activity. Compound 2, 3-
methyl-N-methylpyrazole, MW=295.79, a structural analog of 
Compound 1, is inactive in cellular iNOS inhibition assays. Inhibition of Inducible Nitric Oxide Synthase Expression  Current Chemical Genomics, 2008, Volume 2    3 
Table 1.  N-methylpyrazole-based compounds tested for inhibition of nitric oxide production in RAW264.7 cells (RAW/DAN) and 
A172 cells (A172/DAN) and iNOS protein expression in compound-treated RAW264.7 cells (RAW/Cytoblot). Data are 
representative IC50 values from replicate experiments. 
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AGT TGA GGG GAC TTT CCC AGG C-3’. NFB anti-
body was purchased from Santa Cruz Biotechnologies [8,9]. 
RESULTS AND DISCUSSION 
  To identify small molecules that reduce the production of 
iNOS-derived NO, we developed a homogeneous forward 
chemical genetic screen in the murine macrophage cell line 
RAW 264.7. Stimulation of RAW 264.7 cells with bacterial 
lipopolysaccharide (LPS) and IFN- results in the increased 
expression of a host of inflammatory genes including iNOS 
[10]. The effect of compounds on iNOS activity was quanti-
fied by indirectly measuring the production of NO from 
cells. This approach enables not only the detection of com-
pounds that inhibit iNOS directly, but also compounds that 
act upstream in the iNOS-NO axis. Using this assay, we 
screened a 650,000 compound library using a fully auto-
mated ultra high-throughput robotic system. Compounds 
were tested in single point at 10 μM and hits were confirmed 
in 7-point dose response. A total of 330 compounds (0.05% 
hit rate) demonstrated significant reduction in NO produc-
tion (>30% inhibition) without detectable cytotoxicity. One 
inhibitor identified from this screen, compound 1, shared no 
structural similarity to previously described iNOS inhibitors 
(Fig. 1). Several analogs of compound 1 were synthesized 
and tested in the homogeneous cell-based NO detection and 
other follow-up assays. These analogs provided a cursory 
assessment of the structure activity relationship for the se-
ries. Replacement of the R
1 2-chlorobenzylthio with the 3-
methyl derivative (Cmpd 3) was tolerated, though removal 
of the 2-substituent (Cmpd 4) or addition of a 6-fluoro sub-
stituent (Cmpd 5) reduced activity across all assays. Modifi-
cations to the R
2 oxime through alkylation (Cmpd 6), con-
version to a hydrazone (Cmpds 7 and 8) or replacement with 
a carboxylic acid or amide (Cmpds 9 and 10) greatly reduced 
or eliminated activity. Two additional structurally related 
analogs of merit were identified (Cmpds 11 and 12) with R
1 
sulfones in place of the thio ether and a nitrile in place of the 
R
2 oxime. Compound 12 displayed the most potent in vitro 
activity profile of the series, and the data indicate that the 
oxime is not essential for activity of compounds within this 
chemical series. Strikingly, replacement of the R
3 trifluoro-
methyl with a methyl group (Cmpd 2) resulted in an inactive 
molecule (Fig. 1 and Table 1). In contrast to compound 1, 
which inhibited NO production with an IC50 of 2.8 μM, 
compound 2 was essentially inactive in the NO detection 
assay (Fig. 2A). Demonstrating that its effects are conserved 
across species, compound 1 also inhibited NO production in 
cytokine-stimulated human A172 glioblastoma cells with an 
IC50 of 4.2 μM. As seen in RAW264.7 cells, compound 2 did 
not affect NO production in A172 cells (Fig. 2A). The subtle 
structural difference between compound 1 and compound 2, 
combined with the significant difference in ability of the two 
compounds to block cellular iNOS activity, facilitated a 
pharmacological approach to elucidating the mechanism of 
action of compound 1.  
  Interestingly, a counter screen for biochemical enzyme 
inhibition revealed that compound 1 failed to reduce iNOS 
activity, indicating that the compound might not directly 
inhibit the enzyme (data not shown). A tertiary 384-well 
microplate-based in-cell western blot assay (cytoblot) in 
RAW264.7 cells utilizing an iNOS-specific antibody deter-
mined that compound 1 inhibited LPS/IFN--induced iNOS 
protein expression with an IC50 of 1.5 μM, a value compara-
ble to that calculated from the NO detection assay (Supple-
mental Fig. 1 ). To confirm the cytoblot findings, we per-
formed immunoblot analysis and demonstrated that 10 μM 
compound 1 blocked iNOS expression in RAW264.7 cells. 
This effect was not seen when cells were treated with vehicle 
or compound 2, but was seen when global protein translation 
was blocked in cells using cycloheximide (Fig. 2B,  top 
panel). In contrast to the effects of compound 1 on endoge-
nous iNOS, heterologous expression of recombinant iNOS in 
HEK293 cells was unperturbed by either compound 1 or 
compound 2, whereas expression was reduced in cells treated 
with cycloheximide (Fig. 2B, bottom panel). These data in-
dicate that compound 1 acts upstream in the iNOS pathway 
and reduces NO production in cells by reducing iNOS pro-
tein levels. 
  Next, we tested the effects of compound on cellular iNOS 
mRNA transcript levels. A172 cells and RAW264.7 cells 
were stimulated with proinflammatory factors and treated 
with compounds at a final concentration of 10 μM for 6 
hours before isolating the RNA and performing real-time 
quantitative PCR to determine whether iNOS mRNA levels 
were affected. As seen in Fig. (2C), a statistically significant 
reduction in iNOS transcripts was measured following treat-
ment with compound 1 relative to either compound 2 or ve-
hicle (DMSO). The reduction of iNOS m R N A  c a u s e d  b y  
compound 1 relative to compound 2 ranged from approxi-
mately 4.7-fold in RAW264.7 macrophages (p = 0.01) to 
13.7-fold in A172 cells (p = 0.045). As seen for iNOS pro-
tein, compound 2 had no statistical effect on iNOS mRNA 
levels relative to vehicle (Fig. 2C). These results indicate 
that compound 1 reduces NO production in cytokine-
stimulated cells, at least in part, by reducing cellular iNOS 
mRNA levels. 
  To identify the mechanism whereby compound 1 inhib-
ited iNOS expression and to identify the biological path-
way(s) impacted by compound 1, we then profiled global 
gene expression in A172 cells simultaneously treated with 
cytokine-stimulation media and compound. A significant 
difference was defined as  2-fold change (up or down) in 
mRNA transcript levels with a p value 0.05. In cells stimu-
lated with cytokines for 30 minutes, no significant differ-
ences in gene expression were observed between cells 
treated with compound 1 or compound 2 at 10 μM. How-
ever, as compared to the 30 minute time-point, after 6 hours 
of incubation with proinflammatory cytokines and vehicle, 
approximately 3.8% of genes profiled exhibited altered ex-
pression, consistent with the well documented activation of 
inflammatory signaling pathways [11]. Strikingly, at 6 hours 
there was virtually no difference in the gene expression pro-
file (< 0.1 % of transcripts) of cells treated with compound 2 
and cytokine as compared to cytokine treatment alone. In 
contrast, cytokine stimulated cells treated with compound 1 
displayed a significantly different gene expression profile at 
the 6 hour time-point. A subset of genes with altered expres-
sion in compound 1 treated cells were common to those in-
duced by cytokine stimulation. As anticipated from previ-
ously described qPCR results, iNOS mRNA levels, which 
were induced by cytokine stimulation, were reduced 4.7-fold 
by coincubation with compound 1 (but unaffected by com-
pound 2 treatment). Notably, in addition to iNOS, the tran-
scripts of several other inflammatory mediators normally Inhibition of Inducible Nitric Oxide Synthase Expression  Current Chemical Genomics, 2008, Volume 2    5 
upregulated by cytokines, (TNF, IL1, MCP-2 and I-TAC) 
were downregulated by compound 1 relative to compound 2 
or vehicle (GEO submission GSE7806). Gene expression 
was not universally reduced however, for example, tran-
scripts of IL15  (2.4-fold), chemokine orphan receptor 1 
(CMKOR1,  11.2-fold) and ATP-binding cassette protein 1 
(ABCA1, 3.5-fold) were increased by compound 1 treatment 
(GEO submission GSE7806).  
  Interestingly, in addition to altering inflammatory gene 
expression, compound 1 also affected the mRNA levels of 
multiple genes involved in the UPR. The transcription fac-
tors XBP-1 (2.7-fold), ATF3 (3.2-fold), ATF4 (3.3-fold), and 
CHOP (22-fold) were significantly induced in compound 1-
treated cells. Molecular chaperones ERdj4 (24-fold) and BiP 
(2.7-fold) and ER to Golgi transporters SEC23B (2-fold) and 
SEC31L1 (4-fold) were also significantly elevated by com-
pound 1. Further, Herpud1/ Herp, a membrane-associated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Compound 1 inhibits iNOS enzymatic activity and reduces iNOS protein and mRNA levels. 
Panel A. Compound 1 (Cpd 1) inhibits cellular iNOS activity in both murine RAW264.7 macrophages and human glioblastoma A172 cells at 
10 μM. Compound 2 (Cpd 2) does not affect iNOS activity in either cell-line compared to Vehicle (Veh). Insets show dose-dependent inhibi-
tion of iNOS by Compound 1, with IC50 values indicated. The iNOS inhibitor 1400W (100 M) was used to define 0% enzyme activity (er-
ror bars represent SD, *** p < 0.0001 relative to Cpd 1, differences between Veh and Cpd 2 were not statistically significant). Vehicle does 
not significantly affect NO production relative to no treatment controls (data not shown). Panel B (upper). Immunoblot of endogenous mur-
ine iNOS protein from RAW 264.7 cells after 18 hours of simultaneous LPS/IFN- stimulation and treatment with the compound indicated. 
Compound 1 at 10 μM and cycloheximide (Chx) at 1 μM ablate iNOS protein levels. None of the compounds reduced -tubulin or GAPDH 
protein levels under these experimental conditions (data not shown). Panel B (lower). Immunoblot of recombinant murine iNOS heterolo-
gously expressed in HEK293 cells. Neither Compound 1 (10 μM) nor Compound 2 (10 μM) cause any reduction in iNOS protein levels rela-
tive to vehicle. Samples were normalized for total protein. Panel C. Measurement of iNOS mRNA transcript levels using SYBR-green quan-
titative real-time PCR. RAW264.7 and A172 cells were simultaneously stimulated with pro-inflammatory media and treated with vehicle 
(Veh), Compound 1 (10 μM), or Compound 2 (10 μM) for 6 hours. Transcript levels for iNOS were normalized to GAPDH and data shown 
as relative expression by treatment (error bars represent SD, ** p = 0.01, *** p = 0.0001, # p = 0.045 ). Uninduced RAW 264.7 cells and 
A172 cells contain extremely low quantities of iNOS transcripts, approximately 150-times and 140-times less than compound 1-treated cells, 
respectively (data not shown). 6    Current Chemical Genomics, 2008, Volume 2  Symons et al. 
protein which functions in ER associated degradation was 
upregulated 9.7-fold (Fig. 3A). Changes in the expression of 
several genes identified in the expression profiling study 
were confirmed by independent qPCR analysis (Supplemen-
tal Figs. 2A and 2B). Similar gene expression signatures 
have been described for known ER stressors, including tuni-
camycin and thapsigargin [12, 13] and these effects were 
absent in cells treated with compound 2. These and other 
findings described below suggest that compound 1 may in-
duce the UPR, and as a result, we have named this com-
pound erstressin and its inactive analog compound 2, nos-
tressin.  
  Activation of the UPR gene expression program is initi-
ated by at least three ER transmembrane protein sensors, 
including ATF-6, IRE-1, and PERK. Under normal condi-
tions, all three proteins are maintained in inactive conforma-
tions by Grp78, an HSP70-family chaperone. The binding of 
accumulated unfolded proteins to Grp78 causes the dissocia-
tion of these three complexes and the activation of signal 
transduction. IRE-1 and PERK are both kinases that self-
oligomerize upon release of Grp78. In the case of IRE-1, 
oligomerization-induced autophosphorylation activates an 
internal ribonuclease domain that triggers alternative splicing 
of its mRNA substrate, XBP-1, encoding a bZIP transcription 
factor that activates downstream UPR genes. Oligomerized 
PERK undergoes autophosphorylation and then phosphory-
lates two substrates, the bZIP transcription factor NRF2 and 
elongation factor 2 (eIF2). Cumulatively, these signaling 
events lead to the UPR gene transcription response [14]. 
  To determine if erstressin affects UPR gene expression 
by activating these pathways, we tested for several early 
markers of ER stress signaling. For comparison, we also 
characterized thapsigargin, which induces ER stress by in-
hibiting the Ca
2+-ATPase resident within the ER, thereby 
causing protein misfolding indirectly by disrupting the func-
tion of Ca
2+-dependent chaperones Grp78, Grp94, and cal-
reticulin [15]. Immunoblot analysis of protein extracts iso-
lated from RAW264.7 cells treated with 10 μM erstressin for 
30 minutes showed elevated eIF2 phosphorylation. This 
effect by erstressin was less pronounced than that seen in 
cells treated with 1 μM thapsigargin, but was completely 
absent in cells treated with 10 μM nostressin (Fig. 3B). Next, 
we tested whether the splicing of XBP-1 mRNA by the ER 
transmembrane ribonuclease IRE-1, was altered by erstressin 
treatment. PCR amplification of RNA samples isolated from 
HeLa cells incubated with 20 μM erstressin or 50 nM thapsi-
gargin for 1 hour revealed the presence of alternatively 
spliced XBP-1. Once again, 20 μM nostressin did not induce 
alternative splicing of XBP-1 (Fig. 3C). These findings sug-
gest that, similar to thapsigargin, erstressin activates multiple 
UPR signaling pathways within the first 0.5 - 1 hour of com-
pound treatment. The eIF2 phosphorylation was increased 
by erstressin treatment prior to any detectable changes in 
transcription (within 30 minutes), suggesting that this effect 
by erstressin is upstream of changes in UPR gene expression. 
  To eliminate the possibility that the effects of erstressin 
on iNOS were simply a consequence of reduced cell viability 
or general cytotoxicity, we tested the effects of the com-
pound on cytokine induced A172 cells in several assays. 
Reduced metabolic activity and cell viability as a conse-
quence of the depletion of cellular ATP stores was measured 
in cells treated with compound. Cellular ATP levels were 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Erstressin (Compound 1) induces biochemical markers of ER stress and expression of genes involved in the UPR. Panel A. 
Erstressin increases mRNA levels of ER stress genes. Heat map of normalized microarray data from A172 cells simultaneously induced with 
pro-inflammatory cytokines and treated with indicated compound at 10 M for 6 hours. A selection of UPR-related genes is shown. Data are 
shown as a ratio of expression with compound treatment versus vehicle. Red indicates up-regulation, green down-regulation, and black 
shows no difference between compound and the vehicle control. Panel B. Immunoblot of extracts from RAW 264.7 cells after 30 minutes 
treatment with compound shows elevated phosphorylation of serine 51 of eIF-2 when treated with erstressin (Es, 10 M) or thapsigargin 
(Tg, 1 M), but not with nostressin (Ns, 10 M) or vehicle (Veh) alone. Panel C. XBP-1 rtPCR of RNA isolated form HeLa cells following 
treatment for 1 hour with compound shows the spliced variant (XBP-1s) present in cells treated with thapsigargin (Tg, 50 nM) and erstressin 
(Es, 20 M), but not in cells treated with nostressin (Ns, 20 M). Inhibition of Inducible Nitric Oxide Synthase Expression  Current Chemical Genomics, 2008, Volume 2    7 
unaffected at both 6 hours and 18 hours of treatment with 
either erstressin or nostressin, but substantially reduced in 
cells treated with the positive control, toxoflavin (Fig. 4A). 
In separate experiments, cells were stained with JC-1, a cati-
onic dye which accumulates in the mitochondria under depo-
larized conditions, and can be used to detect reduced viabil-
ity and apoptosis in individual cells. As anticipated from the 
ATP assay, no increase in JC-1-positive cells was observed 
at 6 hours or 18 hours of treatment with either erstressin or 
nostressin, even at concentrations of 10 μM or 30 μM (Fig. 
4B and data not shown). Similar results were obtained using 
an independent apoptosis assay (Annexin V) (data not 
shown). These findings suggest that cytotoxicity is unlikely 
to account for the observed reduction in iNOS expression 
and activity caused by erstressin in A172 cells. 
  To evaluate the potential of erstressin to suppress iNOS 
expression in vivo, we determined the effects of erstressin on 
NO production in a model of inflammatory disease. Admini-
stration of LPS to rodents induces a systemic inflammatory 
response coincident with expression of iNOS [16]. Consis-
tent with its ability to reduce iNOS activity in cell culture, 
intraperitoneal administration of erstressin reduced NO me-
tabolites in rat plasma following LPS stimulation by 50% 
relative to vehicle, p<0.001 (Fig. 5). In a separate experi-
ment, the potent iNOS inhibitor, 1400W, was tested as a 
comparator in the LPS model (Supplemental Fig. 3). Al-
though 1400W is a more efficacious compound (76% reduc-
tion in NO metabolites; p<0.0001), the results are consistent 
with an ability of erstressin to downregulate iNOS in vivo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Erstressin does not cause reduced cell viability or significant apoptosis in A172 cells at 6 hr or 18 hr. 
Panel A. Dose-response curves for cellular ATP levels (a measure of cell viability and metabolic activity) in cells treated with either Er-
stressin (Es) or Nostressin (Ns) at concentrations up to 33 μM. The positive control Toxoflavin (Tf) causes considerable reduction in ATP 
levels at concentrations at or above 10 μM (error bars represent SD, **p < 0.0001, *p < 0.001 as compared to vehicle-treated samples). Panel 
B. JC-1 staining (reduction in mitochondrial membrane potential (m)) in cells treated with vehicle (Veh, DMSO), 10 μM Erstressin (Es), 
10 μM Nostressin (Ns) or 10 μM Toxoflavin (Tf) for 6 hours and 18 hours. Ordinate represents percentage of cell population with positive 
JC-1 mitochondrial staining. Data are representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Erstressin downregulates iNOS activity in vivo. 
Plasma nitrate/nitrite levels, an indirect measure of iNOS activity, 
in normal animals and animals challenged with bacterial lipopoly-
saccharide (LPS), with or without coadministration of erstressin 
(Es) dosed at 30 mg/kg via intraperitoneal injection. Drug and LPS 
were administered simultaneously and plasma nitrates were meas-
ured at 6 hours post-challenge. Each data point represents mean + 
SE from 4-5 animals/ group, * p < 0.001.  8    Current Chemical Genomics, 2008, Volume 2  Symons et al. 
during proinflammatory stimulation, providing for the possi-
bility that a similar mechanism of action to that seen in cell 
culture experiments might downregulate iNOS in certain 
inflammatory disease settings. 
CONCLUSION 
  We have conducted a series of chemical genetic studies 
on iNOS expression that has led to the identification and 
initial characterization of erstressin, a unique methylpyra-
zole-based inducer of the UPR. The chemical structure of 
erstressin is novel and does not immediately reveal clues as 
to the identity of its molecular target(s). Initial structure ac-
tivity relationship studies indicate that the substitution and 
derivitization of the scaffold might enable synthesis of an 
affinity matrix for isolation of cellular targets (TG, CH un-
published observations). The synthetic tractability of the 
series should help facilitate the identification of its receptor 
and provide a useful tool to further investigate upstream 
components of the UPR pathway. 
  A direct relationship between the UPR-inducing proper-
ties of erstressin and the ability of the compound to block 
iNOS expression can be inferred from several findings. First, 
the ability of erstressin to downregulate iNOS expression is 
inextricably linked to its ER stressor activity, as a subtle 
change in chemical structure (nostressin) abrogates the ef-
fects in both pathways. The concentrations of erstressin re-
quired to activate UPR signaling and UPR gene expression 
are the same as those that reduce iNOS mRNA and protein 
expression and enzyme activity. The structurally unrelated 
ER stressor, thapsigargin, also reduced iNOS activity, pro-
tein levels, and mRNA transcripts (data not shown). How-
ever, thapsigargin is somewhat cytotoxic at efficacious con-
centrations, making it difficult to separate a specific effect on 
iNOS from general cytotoxicity. Although CHOP (an apop-
tosis-associated gene correlated with the UPR) expression is 
elevated in response to erstressin treatment in A172 cells, the 
effects on iNOS expression levels or activity are not a conse-
quence of reduced viability or programmed cell death in-
duced by the compound. Importantly, erstressin treatment 
results in specific gene expression changes and does not ap-
pear to cause a global block in transcription. Erstressin does 
not appear to act by interfering with STAT phosphorylation 
(Supplemental Fig. 4A) or NFB DNA binding (Supplemen-
tal Fig. 4B), two key transcriptional activators of iNOS. 
Thus, we propose that erstressin might block iNOS transcrip-
tion by inducing ER stress and/or activating the UPR by an 
as yet unknown mechanism. 
  A negative regulatory role for ER stress in iNOS expres-
sion has been proposed recently for several known and puta-
tive UPR inducers [17]. Interestingly, a similar effect on 
iNOS has been described for resveratrol and its analogs, and 
we speculate that UPR activation might contribute to the 
anti-inflammatory activity of these compounds [18-21]. To a 
large extent however, previous studies have suggested a gen-
eral proinflammatory role for ER stress [22]. While the pre-
cise molecular details whereby activation of the UPR results 
in transcriptional downregulation of iNOS have yet to be 
uncovered, we propose that both pathways could compete 
for common transcription factors or coactivators, resulting in 
the observed transcriptional attenuation. Consistent with this 
idea, NFB, ATF-3, and p300/CBP have been suggested to 
activate transcription of both inflammatory, as well as UPR 
genes [12, 22-24]. Additional mechanisms, such as selective 
or non-selective translational attenuation, may further con-
tribute to the overall reduction in iNOS protein. Our data 
indicate that continued investigation of the relationship be-
tween these two pathways is warranted and could ultimately 
lead to new therapies for the treatment of inflammatory dis-
orders involving iNOS.  
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